ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mirvetuximab soravtansine

Also written as “Mirvetuximab Soravtansine”, “Mirvetuximab soravtansine” and “TAK-853”.

Its studies are mostly in Carcinoma, Ovarian Epithelial · Ovarian Neoplasms · Fallopian Tube Neoplasms · Neoplasms, led by 5 companies.

Drug pageMirvetuximab soravtansine: every studyMany companies study it; this page follows only the 15 they lead. All 28 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Dec 10, 201515 company-led studies, 8 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie115 open or runningphase 3since Dec 10, 2015May 30, 2012Nov 2026phase 2 · NCT05456685
AGO Researchits history only11 open or runningphase 2since Feb 10, 2020Feb 10, 2020none ahead
Huadong Medicineits history only10 open or runningphase 3since Nov 14, 2022Nov 14, 2022none ahead
Pheast Therapeuticsits history only11 open or runningphase 1since Feb 10, 2025Feb 10, 2025Apr 2029phase 1 · NCT06840886
Takedaits history only11 open or runningphase 2since Apr 26, 2024Apr 26, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 30, 2012First study: phase 1 study in NeoplasmsFirst studyNCT01609556 · 206 enrolled · United States, Canada
  2. Jun 9, 2015Named mirvetuximab soravtansineINNProposed as its International Nonproprietary Name in WHO's List 113 · before, TAK-853
  3. Nov 6, 2015Phase 2 study in Carcinoma, Ovarian EpithelialNCT02606305 · 264 enrolled · United States, Belgium, Canada and more
  4. Dec 10, 2015Phase 3 study in Carcinoma, Ovarian EpithelialNCT02631876 · 366 enrolled · United States, Belgium, Bosnia and Herzegovina and more
  5. Dec 17, 2019Phase 3 study in Carcinoma, Ovarian EpithelialNCT04209855 · 453 enrolled · United States, Australia, Belgium and more
  6. Feb 27, 2020Phase 3 study in Carcinoma, Ovarian EpithelialNCT04296890 · 106 enrolled · United States, Australia, Belgium and more
  7. Aug 24, 2021Phase 2 study in Ovarian NeoplasmsNCT05041257 · 79 enrolled · United States, Australia, Belgium and more
  8. Jun 29, 2022Phase 2 study in Fallopian Tube NeoplasmsNCT05456685 · 125 enrolled · United States, Belgium, Canada and more
  9. Jun 30, 2022Phase 3 study in Ovarian NeoplasmsNCT05445778 · 520 enrolled · United States, Argentina, Australia and more
  10. Nov 8, 2024Phase 2 study in Fallopian Tube NeoplasmsNCT06682988 · 110 planned · United States, Australia, Belgium and more
  11. Mar 20, 2025Phase 2 study in Carcinoma, Ovarian EpithelialNCT06890338 · 140 planned · United States
  12. Jul 2, 2025Phase 2 study in Ovarian NeoplasmsNCT07059845 · 400 planned · United States, Australia, Belgium and more

Ahead

  1. Nov 2026Primary completion: phase 2 study in Fallopian Tube NeoplasmsNCT05456685
  2. Apr 2027Primary completion: phase 3 study in Ovarian NeoplasmsNCT05445778
  3. Jan 2029Primary completion: phase 2 study in Ovarian NeoplasmsNCT07059845
  4. Feb 2030Primary completion: phase 2 study in Carcinoma, Ovarian EpithelialNCT06890338

TargetBeta

FOLR1 →read by rule
“An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) ”NCIt, by rule
“Folate receptor alpha binding agent”ChEMBL 37, by rule

Other programs on FOLR1

ProgramCompanyFurthest phaseStudies
rinatabart sesutecanruleGenmabphase 39
torvutatug samrotecanAstraZenecaphase 35
sofetabart mipitecanEli Lillyphase 32
opugotamig olatansineAbbViephase 22
Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901AbbViephase 11
Anti-FRa/Anti-CD3 Bispecific TCE NTB-928ruleteneoseven-incphase 11

Studies

All 11 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07059845Ovarian Neoplasms · United States, Australia, Belgium and more2RecruitingJan 2029400
NCT06890338Carcinoma, Ovarian Epithelial · United States2RecruitingFeb 2030140
NCT06682988Fallopian Tube Neoplasms · United States, Australia, Belgium and more2RecruitingJul 2026110
NCT05445778Ovarian Neoplasms · United States, Argentina, Australia and more3Active, not recruitingApr 2027520
NCT05456685Fallopian Tube Neoplasms · United States, Belgium, Canada and more2Active, not recruitingNov 2026125
NCT05041257Ovarian Neoplasms · United States, Australia, Belgium and more2CompletedDec 12, 202479
NCT04296890Carcinoma, Ovarian Epithelial · United States, Australia, Belgium and more3CompletedNov 16, 2021106
NCT04209855Carcinoma, Ovarian Epithelial · United States, Australia, Belgium and more3CompletedMar 6, 2023453
NCT02631876Carcinoma, Ovarian Epithelial · United States, Belgium, Bosnia and Herzegovina and more3CompletedJan 2019366
NCT02606305Carcinoma, Ovarian Epithelial · United States, Belgium, Canada and more2CompletedMar 12, 2021264
NCT01609556Neoplasms · United States, Canada1CompletedMar 19, 2018206

How it is read

Names in the registry

  • “Mirvetuximab Soravtansine”, 8 entries
  • “Mirvetuximab soravtansine”, 5 entries
  • “TAK-853”, 1 entry
  • “Mirvetuximab soravtansine plus Bevacizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.